

Long-acting Medication Coverage Provincial Formularies

British Columbia

Concerta

Up to a patient's nineteenth birthday

For patients 6 to 18 years of age diagnosed with Attention-Deficit Hyperactivity Disorder (ADHD) who require 12 hours of continuous coverage for significant and problematic disruptive behaviour or problems with inattention that interfere with learning **AND** have been previously tried on one of the following with unsatisfactory results*: immediate or sustained-release methylphenidate **OR** immediate- or sustained-release dextroamphetamine.

**See Special Notes below*

Practitioner Exemptions

- Pediatricians, child psychiatrists, and general practitioners are invited to apply for individual specialist exemption from completing SA forms. See [Collaborative Prescribing Agreement](http://www.health.gov.bc.ca/pharmacare/pdf/cpa-methylphenidate.pdf) <http://www.health.gov.bc.ca/pharmacare/pdf/cpa-methylphenidate.pdf>

Special Notes

- Unsatisfactory results are defined as continuing symptoms of ADHD or functional impairment secondary to ADHD, while on a trial of immediate- or sustained-release ADHD medication of adequate dose and 4-week duration (specific details of dose and duration required, including justification if applicable).
- Coverage is not intended for “performance enhancement” in children or youth who do not have symptoms or functional impairment.

Special Authority Request Forms

- [General Special Authority Request](#)
- <https://www.health.gov.bc.ca/exforms/pharmacare/5328fil.pdf>

Saskatchewan

Concerta is now a full benefit under the Saskatchewan Formulary while Strattera requires Exception Drug Status approval. Saskatchewan physicians and pharmacists should be familiar with the process of requesting Exception Drug Status through the Drug Plan.

The Children's Drug Plan was also effective starting July 1. Under the program, children 14 and under pay no more than \$15 for prescriptions listed on the Saskatchewan Formulary, including Concerta and Strattera (with Exception Drug Status approval). Additional information about the Children's Drug Plan is available at www.health.gov.sk.ca/childrens-drug-plan.

Alberta

None

Manitoba

Biphentin Part 1 Benefit

Concerta Part 1 Benefit

Novo-MethylphenidateER-C Part 1 Benefit

Part One Benefit: Drug products listed under Part 1 of the [Specified Drugs Regulation](#) are benefits with no therapeutic criteria attached to the benefit.

Part Two Benefit: Drug products listed under Part 2 of the [Specified Drugs Regulation](#) are benefits for the length of time and conditions as outlined in the regulation.

Ontario

Therapeutic notes for Adderall, Bipentin, Concerta and Vyvanse

Notes: Patients 6 years of age or older diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

- 1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND
- 2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND
- 3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:

- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:

- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.

Quebec

Dexedrine tablets and spansules, Methylphenidate short acting tablet - covered

Adderall XR, Concerta “Médicament d'exception program” code SN 103 for Children and Adolescents and SN 132 for adults.

Biphentin, children and adolescents “Médicament d'exception” program code SN 103, adults “Patient d'exception” program

Strattera - Médicament d'exception program for children and adolescents, "Patient d'exception" adults.

Vyvanse- Patient d'exception program

New Brunswick

Concerta on formulary

Nova Scotia:

Biphenin is reimbursed as an Exception Status Drug (ESD) for the treatment of ADHD patients (6 to 18 years of age) who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1. Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning, AND
2. Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatric or a general practitioner with expertise in ADHD, AND
3. Have been tried on IR methylphenidate and Slow-Release (SR) methylphenidate with unsatisfactory results.

NFLD/Labrador:

Biphenin is reimbursed as a Special Authorization drug (SA) for the treatment of ADHD patients (6 to 18 years of age) who require 12-hour continuous coverage due to academic and/or psychosocial need, and who meet the following:

1. Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning, AND
2. Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatric or a general practitioner with expertise in ADHD, AND
3. Have been tried on IR methylphenidate and Slow-Release (SR) methylphenidate with unsatisfactory results.

PEI:

Biphenin is reimbursed as an Exception Drug (EDS) for the treatment of children age 6 to 18 years of age diagnosed with ADHD, who require 12 hours of continuous drug coverage due to academic and/or psycho-social need and who meet the following:

- a. Demonstrate significant and problematic disruptive behaviour OR have problems with inattention that interferes with learning; AND
- b. Have been tried on methylphenidate (Ritalin) immediate and sustained- release tablets with unsatisfactory results.

Note: Must be prescribed or recommended by a pediatrician, psychiatrist, or general practitioner with expertise in the treatment of ADHD.

Note: The maximum daily approved dosage will be 1 mg/kg/day to a maximum of 80 mg per day.

Note: Will only be approved for once daily dosing.